Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxonidine in essential hypertension
NCT00160277Phase 3
Key facts
- Status
- Completed
- Start
- Jul 2005
- Countries
- 1
- Sponsor
- Solvay
- Modality
- Small Molecules
- Drugs
- moxonidine
- Conditions
- essential hypertension
01
Overview
Phase 3, open-label, single-arm trial of moxonidine in essential hypertension, sponsored by Solvay. Primary endpoint: Systolic Blood Pressure Reduction. Started Jul 2005; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Moxonidine
Subjects receive Moxonidine in a force-titration schedule.
03
Who it enrols
Ambulatory subjects in India with essential hypertension.
04
Endpoints
Primary
Systolic Blood Pressure Reduction
Secondary
Piggy-back pharmacoeconomic evaluation
Safety and tolerability
Beyond the preview
Go deeper on NCT00160277.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00160277.